In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of UCLouvain, in close collaboration with Willem de Vos, professor at UWageningen, discovered the beneficial effects of an intestinal bacteria, Akkermansia muciniphila1, able to moderate the development of obesity and type 2 diabetes, in mice. In 2017, the team discovered (still in the mouse) that the use of a pasteurized form of Akkermansia leads to an even greater protection than the living bacterium regarding various cardiovascular disease risk factors such as insulin resistance, hypercholesterolemia, or the storage of fat in adipose tissue.
Following these discoveries, the UCLouvain team, in collaboration with the Cliniques universitaires Saint-Luc2, developed a clinical study in order to administer the bacteria to humans. For this, it was necessary to develop the capacity to produce the bacterium in large quantity and to make sure that the tests would be without risk for the participants.
The UCLouvain researchers administered Akkermansia to overweight or obese volunteers, all displaying insulin resistance (pre-diabetes type 2) and metabolic syndrome, in other words, having several elevated risk factors for cardiovascular diseases. The volunteers were randomly divided into 3 groups (placebo, live bacteria and pasteurized bacteria) and were asked not to change their dietary habits or their physical activity. Akkermansia was provided as a nutritional supplement.
The primary goal of this UCLouvain study was to demonstrate the feasibility of daily ingesting Akkermansia for 3 months, without risk. Clara Depommier and Amandine Everard, UCLouvain researchers, observed excellent compliance (the supplements were easy to ingest) and tolerance (there were no side effects) in the groups taking live or pasteurized bacteria.
The conclusions are clear: the tests in humans confirm what had already been observed in mice. Ingestion of the (pasteurized) bacterium prevented the deterioration of the health status of the subjects (pre-diabetes, cardiovascular risks). Even better, the researchers observed a decrease in inflammation markers in the liver, a slight decrease in the body weight of the subjects (2.3 kg on average)3 as well as a lowering of cholesterol levels. In contrast, the metabolic parameters (insulin resistance or hypercholesterolemia) in placebo subjects continued to deteriorate over time.
Who does it benefit? According to the WHO, one in three people die every day from cardiovascular disease worldwide. In Western countries, one in two people is overweight and has increased cardiovascular risks. This research of the UCLouvain would limit these risks and therefore potentially have an impact (limit the effects) on half of the population, if properly used.
In conclusion, this pilot study demonstrates the feasibility of administrating (pasteurized) Akkermansia bacteria to humans in the form of a food supplement and reports encouraging results on the effectiveness of the Akkermansia-based dietary supplements to reduce cardio-metabolic risk factors. These results pave the way for a large-scale study, to confirm/elaborate these first results, but also endorse the commercialization of the bacteria as food supplements.
A generic email address has been created for the public who wants more information about Akkermansia bacteria: [email protected].
Learn and see more: A bacteria likely to reduce the cardiovascular risks of 1 in 2 people
The Latest on: Akkermansia
[google_news title=”” keyword=”Akkermansia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Akkermansia
- What is Akkermansia, the probiotic you didn’t know you needed?on July 16, 2024 at 7:52 pm
We’ve even gotten familiar with probiotics (the live bacteria that can improve our gut health), but there’s one that remains relatively unrecognised: Akkermansia Muciniphila. Read on for everything ...
- I Took the “Ozempic Probiotic”—Here’s What Happenedon July 15, 2024 at 7:33 pm
We earn no revenue from the sale of this product, nor is the brand sponsoring this story. But for anyone abstaining from weight loss injectables for ethical or other reasons, our team may have ...
- Microbiota from young mice counteracts susceptibility to age-related gout through modulating butyric acid levels in aged miceon July 14, 2024 at 5:00 pm
This important study shows that age-related gut microbiota modulates uric acid metabolism through the NLRP3 inflammasome pathway and thereby regulates susceptibility to age-related gout. Whereas some ...
- Original Founders of Akkermansia Muciniphila Bring First Gut Health Product to U.S. Consumer Marketon June 27, 2024 at 1:11 am
WILMINGTON, Del., June 27, 2024 (GLOBE NEWSWIRE) -- The Akkermansia Company, creator of clinically proven, next-generation gut health solutions, is pleased to announce its launch into the U.S ...
- Top 8 Best Akkermansia Muciniphila Supplements in 2024on June 25, 2024 at 5:00 pm
The bacterium Akkermansia muciniphila, which lives in the human intestines, is linked to a range of health advantages. These benefits include, but are not confined to, improving gut health ...
- How to get a body like ‘biohacker’ Ben for £1,000on June 14, 2024 at 8:30 am
Ben has weekly NAD IV therapy. Akkermansia: For good measure he suggests this cholesterol-lowering probiotic (£49.49/30 from Healf). For transparency, I’m already a pill popper and take a daily ...
- Doctor Says These Foods and Supplements Mimic Ozempic Effectson January 12, 2024 at 5:42 am
If you've ever actively tried to lose weight, you know that it can be challenging, to say the least. Thankfully, weight-loss drugs are now an option for those who haven't had success with ...
- How to be good to your gut (And why it matters)on March 15, 2017 at 1:47 pm
Here are a few things you can do to encourage your bacteria to flourish. Higher numbers of the bacteria Akkermansia are found in people who are naturally slim, leading to suggestions that these ...
via Bing News
